Medtronic PLC vs Weibo Corp — how do they compare? Medtronic PLC trades at $90.61 (market cap $116.07B), while Weibo Corp trades at $7.87 (market cap $1.93B). The key difference: Medtronic PLC is far larger — about 60.1× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.75%). Which is the better fit depends on your goals.
| MDT | WB | |
|---|---|---|
Market Cap | $116.07B | $1.93B |
Sector | Health | Media |
52-Week High | $105.35 | $12.83 |
52-Week Low | $73.75 | $7.20 |
Enterprise Value | $134.82B | $1.20B |
Dividend Yield | 3.18% | 7.75% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Weibo (WB) trades at $7.76, down 2.82% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 5.5 and P/B of 0.5. The company maintains strong profitability with 21.15% net margins and $449M net income in 2025, but has missed earnings expectations for three consecutive quarters. Cash flow trends show volatility, with 2024 net cash flow negative $694M despite solid operational performance.
The stock presents a value opportunity given deep discount to balance sheet value, but faces competitive pressures and user engagement challenges. Analyst sentiment is mixed with 45% buy ratings, while technical indicators suggest near-term weakness. Key risks include Chinese regulatory environment and competition from Douyin/WeChat.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →